Lucid Capital upgraded INmune Bio (INMB) to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company’s CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune’s pipeline for the upgrade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
- INmune Bio Highlights CORDStrom RDEB Program and IP Strength
- INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
- INmune Bio to Present New CORDStrom Phase III Data
- INmune Bio Advances CORDStrom Toward Rare Disease Commercialization